← All candidates
Three insider buys in the last year — $89.6K in all.
15 filings on record.
FBLGFibroBiologics, Inc.
NasdaqCM · Healthcare · $9.81M
$1.44
-7.10% · Sep 15
Three insider buys in the last year — $89.6K in all.
Nothing in the last fortnight.
Price · 1Y · daily● 3 buys◆ 8 8-K
▸ hover a marker for the filing · drag to zoom · daily bars sharpen to 30-min on close ranges · 4 moves explained
Reverse-split 1×. When a company does a reverse split, the chart rewrites its old prices to look far bigger than they really were — so the high early prices here aren't what FBLG ever actually traded at. The drop is real, but those huge old numbers aren't.
AI brief · from the filings on this pagePro
The filings, the score and the setup on this page, read for you in about ten seconds — what the insiders did, and what stands against it.
Market cap
$9.81M
Float
6.0M
86% public
Short % float
Pro
The buyers
▸ each insider's past open-market buys, measured ~6 months (120 trading days) later, against the S&P over the same spans · split-adjusted · pre-scheduled 10b5-1 plan trades excluded · past outcomes, not predictions
General Counsel
Garcia Ruben A
Bought $47.6K on Dec 11 — 140,000 sh @ $0.3400, held direct, 100% of their stake.
0 of 1 position beat the S&P
Chief Financial Officer
Davis Jason
Bought $29.0K on Mar 2 — 70,000 sh @ $0.4139, held direct, 100% of their stake.
0 of 1 position beat the S&P
Chief Scientific Officer
Khoja Hamid
Bought $16.8K on May 27 — 20,000 sh @ $0.8400, held direct, 64% of their stake.
0 of 1 position beat the S&P
The record
newest first
DateTypeInsiderOf stakeShares @ priceValue
Context
Wall St
$12.50 avg target
+768.1% vs today · 2 analysts
▸ relayed analyst opinion, which tends to run optimistic — not our forecast or advice
Earnings · EPS vs forecast
3 of 4 quarters beat
Q2 '26−$0.66 act+$0.27
Q1 '26−$1.33 act+$0.02
Q4 '25−$0.60 act+$1.40
Q3 '25−$2.60 act−$0.30
Coverage
FibroBiologics advances diabetic ulcer trial with new drug shipment to AustraliaProactive · 2w agoEXCLUSIVE: FibroBiologics Doses First Patients In Diabetic Foot Ulcers Clinical TrialBenzinga · 06-03Is FibroBiologics, Inc. (FBLG) Advancing Toward a Breakthrough Psoriasis Treatment With CYPS317 Data?Insider Monkey · 06-02
The file stays open
15 filings on record.
The next one will be too.
▸ SEC EDGAR · FINRA · Nasdaq — public sources only · research, not advice